How Long Does It Take for a GLP-1 to Start Working?

"How long until this works" is a different question from "what dose am I on which week" — that second question is answered by the labeled titration schedule. This article answers the first one: how soon does a GLP-1's appetite and GI effect actually kick in after an injection, and how soon does that translate into weight loss you can see on the scale, according to the pivotal trial data rather than anecdote.

The pharmacological clock starts within days, not hours

Semaglutide (Wegovy) and tirzepatide (Zepbound) are both once-weekly injections precisely because of how long they stay active in the body. Per Wegovy's FDA prescribing information, semaglutide has an elimination half-life of approximately one week, meaning it remains in circulation for roughly 5 to 7 weeks after a single dose¹. Per Zepbound's FDA prescribing information, tirzepatide's elimination half-life is approximately 5 to 6 days². Practically, that means a single injection isn't a switch that flips and fades within a day — its effect builds as blood levels accumulate over consecutive weekly doses, plateauing only after several doses at a given level. That's also why appetite suppression is commonly reported within the first 1 to 2 weeks even at the lowest, sub-therapeutic starting dose (2.5 mg for tirzepatide, 0.25 mg for semaglutide) — the receptor-level effect on appetite and gastric emptying does not wait for you to reach a "real" dose, it starts acting from the first injection, just at a lower intensity than at maintenance dose³.

What the trial data actually show at early timepoints

The pivotal obesity trials were both built to run long — semaglutide's STEP 1 measured its primary endpoint at 68 weeks, and tirzepatide's SURMOUNT-1 measured its primary endpoint at 72 weeks⁴⁵ — because meaningful weight loss on a GLP-1 accrues gradually through months of dose escalation, not in a single early spike. But "gradual over a year" doesn't mean "invisible for months." A post hoc analysis of SURMOUNT-1 specifically split participants by how much weight they had lost by week 12 — right around the end of tirzepatide's dose-titration period — into "early responders" (≥5% weight reduction by week 12) and "late responders" (under 5% by week 12)⁶. The result: 82% of participants (1,267 of 1,545 analyzed) were already early responders, meaning most people on tirzepatide had already lost a clinically meaningful 5% of body weight within the first 12 weeks of treatment. Of the 18% who were slower to respond, 70% had still reached 5% weight loss by week 24, and 90% had reached it by week 72 — the mean time for a late responder to hit the 5% mark was 24.8 weeks⁶. In other words, even the slower-responding minority of trial participants were not stalled indefinitely; they simply needed more weeks on treatment to reach the same milestone most people hit by week 12.

A directly comparable early-responder breakdown hasn't been published for semaglutide's STEP 1 in the same post hoc format, so we won't invent a percentage here — but STEP 1's own published weight-change-over-time data show the treatment group separating from placebo progressively over the trial's early months, consistent with the same general pattern: measurable average weight loss well before the 68-week primary endpoint, continuing to accrue through the dose-escalation period rather than showing up all at once⁴.

Why the scale can lag what you're feeling

This is the gap that causes most of the "is this even working" doubt in the first month. Appetite suppression is a subjective, day-to-day signal — smaller portions, less interest in snacking — and it can show up within the first couple of weeks, even at a starting dose too low to expect much weight-loss effect from on its own. The number on the scale is a lagging indicator: it reflects an accumulated calorie deficit over days and weeks, not a single day's appetite change, and for the first several weeks you're also on a deliberately low, sub-therapeutic dose by design³. Feeling the appetite effect in week 1 or 2 while the scale barely moves yet is not a sign the drug "isn't working" — per the trial data above, it's the expected order of events, with the visible weight change typically following within the next several weeks as the dose steps up.

GI side effects follow the same early timeline

The same buildup pattern that governs appetite suppression governs the gastrointestinal effects people ask about when they search "when do Zepbound side effects start." Nausea, constipation, diarrhea and related GI effects are the dominant adverse-event category in both drugs' pivotal trials, and they concentrate around the start of treatment and around each dose increase rather than persisting flat throughout⁵³ — see tirzepatide side effects and semaglutide side effects for the actual trial-reported rates and how long they typically last. That timing is one more reason the titration schedule exists the way it does: each step-up is a fresh, smaller version of the same "onset" question this article answers, not just a bigger number on the label.

This is not the same question as the titration schedule

It's worth being explicit about the distinction, because the two get conflated constantly: the titration schedule tells you which milligram dose you're on in a given week, on a fixed calendar set by the FDA label. This article is about a separate, physiological question — how quickly the drug you just injected, at whatever dose you're currently on, starts producing an effect. The titration schedule explains why the first month is deliberately low-dose; this article explains why you can still feel something during that low-dose month, and roughly when the trial data say the scale should start reflecting it.

What this means if it feels like nothing's happening yet

If you're several weeks in with no appetite change and no scale movement at all, that's worth a direct conversation with your prescriber rather than an assumption that you're simply a "late responder" — the trial data above describe averages across over a thousand people, not a guarantee for any one person. If you did have an early response and it has since slowed after weeks or months of visible progress, that's a different, later-stage phenomenon — see the GLP-1 weight-loss plateau for what the evidence says about that separate situation, which is not what this article covers. For the mechanics of the injection itself, see how to inject semaglutide; if you're still deciding between molecules, semaglutide vs tirzepatide covers the efficacy and price trade this timeline data feeds into. The trial and label sources behind this article are indexed in our research library. Not medical advice — see our medical disclaimer and talk to your prescriber about what you're experiencing and when.